Memory Lenses Model 2019 3.jpg
 

Bringing Hope to Millions with a Patent-Pending, Non-Drug Treatment for Alzheimer’s

 

The Easy to Use, Non-Drug Approach to Treating the Cause of Memory Loss

 

Now, as easy as putting on glasses, Alzheimer’s sufferers can apply beneficial therapy with MemorySPEX™ in the comfort of their own homes, or in any setting, for as little as twenty minutes a day, while allowing them to watch TV, spend time with loved ones, or partake in other normal activity.

 
Now you can have faith that you can get your loved ones back home, back from the brink, back to themselves, back to remembering who you are, back to financial control, back to hope.
 

Groundbreaking research is advancing treatment options in a historic way. Drugs are clearly not the answer for Alzheimer’s sufferers. Our new product MemorySPEX™ makes this groundbreaking research available for the first time to millions globally who are desperate for relief from fear, emotional suffering, and the intense financial strain of Alzheimer’s.

 

We’re a Michigan startup that wants to topple Big Pharma—and we just might.

 

We knew we had to upend Big Pharma in every way, breaking every rule by deciding to bring our non-drug, non-invasive, easy-to-use, product direct to millions of sufferers at a reasonable cost.

 

Founded in February 2018, MemorySPEX is getting ready to launch its patent-pending product direct to patients in the United States, Canada, Australia and the United Kingdom in 2019. Utilizing stroboscopic technology, our MemorySPEX look like a pair of ordinary glasses, but deliver visual and audio stimulation to the brain, which has been shown in recent research by a preeminent university published in the medical journal Nature to reduce plaque in the brain that causes Alzheimer’s.

 

“My wife has been the first in a MIT Alzheimer’s trial for 7 months. The 40 hertz treatment worked for my wife and all the other 10 participants. The treatment mitigates the process of plaque destruction, gives the patient a euphoric response and keeps them from going into rest homes. One million people not going to rest homes for one year will save the U.S. about $60 billion every year. MIT does not own 40 hertz anymore than GM owns 40MPH. A cheap controller can help 5 million dementia sufferers in the U.S. and their families and we cannot wait for MIT and the FDA to get off their bureaucratic asses.” Ed Gleason, husband of Alzheimer’s patient Peg Gleason. https://www.alternet.org/2017/12/brain-wave-treatment-alzheimers-promising-first-human-subject-left-behind/

 
“Stroboscopic technology is not new, but it’s application in the treatment of Alzheimer’s disease is. NASA developed stroboscopic therapy to treat space sickness in astronauts returning from the MIR space station decades ago, and superstar athletes have adopted it as a performance-enhancing tool with spectacular results in the last few years.”

Alzheimer’s disease has become a global epidemic with no end in sight. Besides the heart-breaking personal suffering of patients and their caregivers, its exploding costs will put budget-busting demands on Medicare as the numbers of sufferers explode in the next 30 years. Add to that the fact that current Alzheimer’s drugs only treat the symptoms and not the cause, and you have a desperate plea for an alternative treatment from patients, physicians, caregivers and family members that is rising to a critical pitch.

Company Founder & CEO Kim Lavine has transformed the lives of millions through her appearances on the Today Show, Rachel Ray, Good Morning America, NBC & ABC news, CNN, CNBC, FOX, NPR, Oprah & Friends Radio Network, LifetimeTV.com, and features in USA Today, Country Living, Guideposts, Inc, Business Week, Entrepreneur, Women’s World, and Forbes to name a few.

Prior to founding MemorySPEX™ in February of 2018, Founder and CEO Kim Lavine spent two and a half years pioneering consumer, athletic, military and medical markets for stroboscopic technology as Partner in a previous company; their technology was adopted by some of the biggest names in sports as attested by interviews on ESPN and in GQ. She had just begun to explore the medical applications for the improvement of cognitive functions that the treatment was providing athletes when the research in Nature broke showing the reduction of plaque in the brain that causes Alzheimer’s from stroboscopic therapy.

Kim Lavine - Founder/CEO

Kim Lavine - Founder/CEO

“I’ve done a lot of exciting things, but I’ve never had the opportunity to change the world for millions of people suffering globally…until now.” Kim Lavine, Founder/CEO
sunglasses

Be the first to use this ground-breaking technology. Pre-order now for a 50% discount and a 100% money-back guarantee.

Our Technology

We’re disrupting the global medical and pharmaceutical industry, and pioneering the future of medical wearable technology, bringing hope to millions suffering from Alzheimer’s disease through an easy to use, patent-pending, non-drug approach.

Decades of clinical and university studies have resulted in the adoption of stroboscopic technology for the improvement of cognitive functions in everyone from Mir astronauts to current-day superstar athletes.

How Does It Work in LAYMAN’S TERMS?

Certain electrical oscillations (waves) in the neurons’ network interaction of the brain are shown to be out of sync in Alzheimer’s sufferers. The frequency range of the stroboscopic effect from our MemorySPEX, along with auditory stimulation (at optimal range of 40Hz) produces gamma oscillations (unseen wave from the lenses through brain) which are shown to reduce the toxic protein on the neurons’ Beta Amyloid (termed ‘plaque’).

This reduction of these toxins in the visual cortex and hippocampus parts of the brain improves cognitive function.

Unlike conventional strobe lights, which emit burst of flashing lights (an invasive stimuli), MemorySPEX do not emit any type of light whatsoever. In fact, it produces a strobe-like effect by momentarily blocking out natural ambient light (a noninvasive stimuli) in much the same way as blinking does. By using LCD (Liquid Crystal Display) lens technology, MemorySPEX have a functionality of blocking ambient light by electronically switching the lenses from clear to opaque, much like shaded sun glasses. There is no obtrusive light that enters the eyes except natural daylight.

Patient/Doctor Portal

We’re building a patented web application interface, creating a new system of patient care including cost control and Early Intervention.

MemorySPEX is going beyond delivering an alternative treatment through our medical wearable technology, we’re also building a ‘Doctor-Patient Portal’ designed to put unprecedented control in the hands of patients and doctors, while also providing peace-of-mind monitoring for family and caregivers, who suffer almost unbearable worry and guilt as they watch loved ones’ crippling decline.

Memoryspex system.jpg
Our patent expands the use of existing technology to medical applications, providing the consumer with the choice to try our safe, non-drug and non-invasive therapy under the supervision of their doctor’s care and in concert with existing drug regimens.

Our World Class Team

Our first priority at MemorySPEX will always be to serve the urgent need of Alzheimer’s sufferers and their caregivers with empathy, respect, and integrity, with the goal of delivering hope to millions living with this debilitating disease.

We’re committed to bringing a new generation of non-drug related medical solutions direct to consumers on an expedited timeline at a reasonable cost through the rapid-adoption of pioneering research. Our company is built on the past success of our Founders, who have a demonstrated track record for bringing innovative ideas to the global marketplace. Our combined experience spans decades and includes launching, management and growth of national and international businesses, leveraging design, marketing, sales, fiscal management, engineering and operational expertise.

Kim Lavine - Founder/CEO

Kim Lavine - Founder/CEO

Founder/CEO Kim Lavine has spent over three and a half years in a pioneering role researching and developing consumer, medical and military market opportunities for stroboscopic technology, recognized in major national publications through its adoption by superstar athletes in the NBA and NFL. (https://www.youtube.com/watch?v=_wK-8WhxE9s)

As a result of Ms. Lavine’s years of leadership in research and development of consumer, medical and military markets for stroboscopic wearable-tech, MemorySPEX is able to leverage this expertise to fast-track a go-to-market wearable-tech appliance, with a very short timeline for delivery to the consumer marketplace.

Craig Tiggleman - Advisor

Craig Tiggleman - Advisor

Craig is the Chairman, CEO, and Co-Owner of his family’s dynamic and successful third generation business. He has led the 86 year-old entity for over 20 years, navigating through numerous acquisitions, the sales of major divisions, and repositioning through the Great Recession, increasing revenues from $16 million annually to over $100 million. He brings skills in leadership, fiscal management, sales, and contract negotiations. 

Craig has been involved with numerous startups in services, investment real estate, and technology. He also helped initiate, and continues to lead and advise, urban education, arts, and addiction treatment organizations. He is eager for the opportunity to offer his expertise to such an exciting business with a meaningful purpose of helping those suffering with Alzheimer’s Disease.

Richard Alligan - COO

Richard Alligan - COO

Richard will use his extensive engineering background and 25 years experience of leading operational, business and technical sales teams across three continents to grow MemorySPEX smoothly.

With a humorous ‘can do’ attitude no matter the task, he is delighted about taking on the role of Chief Operating Officer in bringing our global-reaching positive project to millions through the management of production and international distribution rights.

Chokha Palayamkottai - CTO

Chokha Palayamkottai - CTO

CTO of AMCHART and AMSYS Blockchain, Chokha has more than twenty years of experience in software development, architecture and design. He is experienced in the areas of Blockchain, AI, Distributed, Scalable and Parallel computing. Chokha leads the development and implementation of AMSYS's blockchain product strategy, AMCHART initiative platform and AMSYS Capital software platform.

Chokha is experienced in successfully running large collaborative customer focused technology teams for global fortune 500 companies and startups, transforming, digitizing and enabling the core business and leveraging key technologies. Chokha was a mentor at Kyyba Xcelerator and was part of the TiE Charter Member and a co-chair for Artificial intelligence track for TiE Midwest region.

Terry Cross - Advisor

Terry Cross - Advisor

Terry Cross has helped many entrepreneurs and investors build substantial wealth through his career on Wall Street and the very early days of the Internet in Silicon Valley, where he was involved in the early formation of such companies as Netscape, Google, Inktomi and Napster. After leaving Silicon Valley, Mr. Cross returned to Michigan where he was instrumental in assisting entrepreneurs in raising a $100 million of funding over ten years from local, national and international resources, delivering billions in returns to investors. He was a member of MIT’s Laboratory for Manufacturing and Productivity, Co-Founder of the Michigan Venture Capital Association, Board Member of the Great Lakes Angels, and Board Member of Automation Alley’s Entrepreneurial Initiative of Southeast Michigan.